A Boston-area biotechnology firm announced it has received a patent titled "Carboxylated Psilocybin Derivatives and Methods of Using" for its EVM301 series of molecules to treat a range of mental health disorders.
Attachments
Disclaimer
Enveric Biosciences Inc. published this content on 02 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 October 2023 16:01:08 UTC.
